{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T21:32:29Z","timestamp":1777757549756,"version":"3.51.4"},"reference-count":13,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Interleukin (IL)-23 exerts its effects by activating Th17 cells, resulting in high neutrophilic infiltration in the colonic mucosal epithelium. We have developed a scoring method for refining the Geboes score Grade 3 to identify active ulcerative colitis (UC) patients with high epithelial neutrophilic infiltration (Geboes Grade 3.2 or 3.3). Methods: Colonoscopy and histology findings were assessed using the Mayo endoscopic subscore (MES) and the Geboes score Grade 3. The percentage of crypts with neutrophilic infiltration, which was calculated as the number of crypts with neutrophilic infiltration\/total crypts in a glass slide, was used to subclassify the Geboes score Grade 3 into Grades 3.0, 3.1, 3.2, and 3.3. Results: This scoring method was then applied to 30 enrolled patients (20 men; median age: 46 years), yielding the following distribution: Geboes Grade 3.0 in six (20%) patients, Grade 3.1 in seven (23%) patients, Grade 3.2 in sixteen (53%) patients, and Grade 3.3 in one (3%) patient. Of the 18 UC patients with MES 2, 5 (28%) were classified as Grade 3.1 and 12 (67%) were classified as Grade 3.2. One of the IL-23 antagonists, mirikizumab treatment, resulted in clinical and endoscopic improvements in 10 active UC patients who were classified as Geboes score \u2265 3.2. Conclusions: We developed a novel Geboes score Grade 3 scoring method and applied it to 30 patients; approximately 60% were classified as Grade 3.2 or higher. This method may help to identify UC patients who are likely to respond effectively to IL-23 antagonists.<\/jats:p>","DOI":"10.3390\/jcm14155180","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:44:45Z","timestamp":1753184685000},"page":"5180","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of Ulcerative Colitis Patients with Elevated Neutrophilic Infiltration in the Colonic Mucosal Epithelium Using the Komagane Subclassification of the Geboes Score Grade 3"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4959-8936","authenticated-orcid":false,"given":"Satoshi","family":"Ukai","sequence":"first","affiliation":[{"name":"Digestive Disease Center, Showa Inan General Hospital, Komagane 399-4117, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichitaro","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Terashima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Showa Inan General Hospital, Komagane 399-4117, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Digestive Disease Center, Showa Inan General Hospital, Komagane 399-4117, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-1025","authenticated-orcid":false,"given":"Akira","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Digestive Disease Center, Showa Inan General Hospital, Komagane 399-4117, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"International Organization for the Study of IBD.STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1055\/s-0042-1758048","article-title":"Medical treatment options for ulcerative colitis","volume":"35","author":"Sleiman","year":"2022","journal-title":"Clin. Colon. Rectal. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103017","DOI":"10.1016\/j.autrev.2021.103017","article-title":"The influence of cytokines on the complex pathology of ulcerative colitis","volume":"21","author":"Nakase","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.05.016","article-title":"Can IL-23 be a good target for ulcerative colitis?","volume":"32\u201333","author":"Allocca","year":"2018","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1136\/gutjnl-2014-307477","article-title":"Comparing histological activity indexes in UC","volume":"64","author":"Bressenot","year":"2015","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial","volume":"298","author":"Rachmilewitz","year":"1989","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1148\/radiol.2282011860","article-title":"Measurement of observer agreement","volume":"228","author":"Kundel","year":"2003","journal-title":"Radiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/MIB.0b013e318280e75f","article-title":"Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis","volume":"19","author":"Lemmens","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pan, Y., Yang, W., Tang, B., Wang, X., Zhang, Q., Li, W., and Li, L. (2023). The protective and pathogenic role of Th17 cell plasticity and function in the tumor microenvironment. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1192303"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wu, X., Tian, J., and Wang, S. (2018). Insight into non-pathogenic Th17 cells in autoimmune diseases. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01112"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5180\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:13:49Z","timestamp":1760033629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":13,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14155180"],"URL":"https:\/\/doi.org\/10.3390\/jcm14155180","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}